FDA Approves Uplizna for Chronic Inflammatory Condition IgG4-RD

FDA Approves Uplizna for Chronic Inflammatory Condition IgG4-RD

Uplizna is the first approved treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition that can affect multiple organs. It has a price of $140,248.50 per dose.

FDA grants breakthrough status for Amgen’s Uplizna to treat IgG4-RD

This decision is based on the randomised MITIGATE trial data, which showed the antibody’s potential to reduce disease activity by minimising flares in individuals, upholding its established safety The post FDA grants breakthrough therapy status for Amgen’s Uplizna to treat IgG4-RD appeared first on Pharmaceutical Business review.